FDA OKs immune-boosting drug for advanced bladder cancer

(AP) – U.S. regulators have approved a new drug that harnesses the immune system to treat advanced bladder cancer.

The Food and Drug Administration on Monday approved Imfinzi (im-fin-ZEE’) along with a companion diagnostic test for identifying which patients are most likely to benefit from it.

Imfinzi, also known as durvalumab, is part of a new generation of immuno-oncology drugs, which stimulate the immune system to help fight cancer.

AstraZeneca, Imfinzi’s developer, says the average monthly list price for Imfinzi is roughly $15,000, but varies with the patient’s weight. It’s infused every two weeks.

Bladder cancer is the sixth most common type of cancer in the U.S., and is usually fatal when it recurs.

AstraZeneca is testing the drug against numerous cancers.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s